🔗 Share this article

As the US undertakes unprecedented changes to its vaccine recommendations, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based sports physician and public health researcher who first made her name by questioning Covid shots in the pandemic and has zeroed in on alleged fatalities following Covid immunization in her recent position at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Program

Health officials planned to announce radical revisions to the childhood vaccine schedule recently, aligning the US with the Danish vaccine program, sources say – a substantial departure that would place the US at odds with many the international standard with insufficient data for improved outcomes. This reveal has been pushed back until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to present at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth person to head the center this calendar year.

A Shift at the FDA

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending specific pediatric vaccine recommendations in the US to become more in line with Denmark, a nation with comprehensive healthcare and a population about the population of Wisconsin’s.

To date comments, she has kept her attention on immunizations – typically the purview of Prasad, director of the FDA’s vaccine center – rather than medication approval.

Questions Over Expertise

The appointee has no apparent experience in medication creation, oversight or administrative roles, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past commissioners of the center would “grasp legal statutes and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that former directors who led CBER have had.”

CDER has an vast workload at the agency, she emphasized.

“Everybody just zeroes in on the new drug program, but the generic drug division clears thousands of generic medications. There is also a biosimilars program, non-prescription drug unit and more, and every single one must be managed,” she noted. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial administrative aspect to the job, which oversees over 5,000 employees. “It is a massive management job, if you do it right,” the former official added.

Agency Reaction and Disputed Programs

Regarding inquiries about Dr. Høeg's fitness for the role and whether this selection represents more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “inquiries are based on inaccurate premises”.

“This background is consistent with the duties of her job,” the spokesperson said, noting the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg inherits the agency head's new fast-track approval initiative, a disputed one-day therapy clearance system that allegedly troubled her former heads. “By what process are these therapies being chosen for this fast-track system? Who makes the decisions?” Howard said. “There’s a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards laxer rules of most medications, except for immunizations.”

Established History on Vaccines

With vaccines, Høeg has a more documented, if problematic, history, Howard said. She released a research paper using unverified volunteer-provided data to determine the frequency of heart inflammation following COVID-19 immunization. She advised the Florida surgeon general Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the incoming federal leadership encompassed revising regulations for novel immunizations and ending “optional” immunizations, she stated following the vote on a podcast. At the agency, Dr. Høeg has according to sources proposed preventing teenage boys from getting Covid vaccines.

“She is an complete ideologue who starts off with her preconceived notions and works backwards to retrofit the data in a very disingenuous, fraudulent way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow contrarians, {like|